The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells

EGR1 expression: A calcium and ERK1/2 mediated PPARγ-independent event involved in the antiproliferative effect of 15-deoxy-Δ12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells

(2011) Sarra Chbicheb et al.   BIOCHEMICAL PHARMACOLOGY

Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism

(2011) Tunde O. Akinyeke et al.   CANCER BIOLOGY & THERAPY

Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARγ-dependent and PPARγ-independent pathways

(2011) Besstina E. Lyles et al.   CELL CYCLE

How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?

(2010) Yohannes Mebratu et al.   CELL CYCLE

Troglitazone, a Ligand of Peroxisome Proliferator-Activated Receptor-γ, Stabilizes NUCB2 (Nesfatin) mRNA by Activating the ERK1/2 Pathway: Isolation and Characterization of the HumanNUCB2Gene

(2010) Masanobu Yamada et al.   ENDOCRINOLOGY

The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells

(2010) Patrice E. Moss et al.   EXPERIMENTAL CELL RESEARCH

A Novel Mechanism by Which Thiazolidinediones Facilitate the Proteasomal Degradation of Cyclin D1 in Cancer Cells

(2008) Shuo Wei et al.   JOURNAL OF BIOLOGICAL CHEMISTRY